Spero Therapeutics (SPRO)

• Market cap: $70.5M
• 1 day: -0.82%
• 5 days: 0.83%
• 1 month: -1.63%
• 3 months: -59.4%
• 6 months: -47.16%
• Year to date: -48.51%
• 1 year: -43.46%
• 5 years: -93.33%
• 10 years: -89.48%
• Sector: Healthcare
• Industry: Biotechnology

About: Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Employees: 25